Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert, +22

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaElderly PatientsMedicineBi-weekly Chop-14 +5

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, +17

The Lancet Oncology

Hematological MalignancyLymphoid Neoplasia6-Year ResultsMabthera International TrialMedicine +7

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, +11

Blood

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert, +40

The Lancet

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

Carsten Müller, Niels Murawski, Martin H. J. Wiesen, +12

Blood

Suboptimal dosing of rituximab in male and female patients with DLBCL

Michael Pfreundschuh, Carsten Müller, Samira Zeynalova, +9

Blood

Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group

Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova, +14

Journal of Clinical Oncology

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL

Niels Murawski, Michael Pfreundschuh, Samira Zeynalova, +11

Annals of Oncology

Dense-r-chop-14 TrialClinical TherapeuticMedicinePharmacotherapyPharmacology +4

A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Norbert Schmitz, Lorenz Truemper, Krimo Bouabdallah, +37

Blood

Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).

Michael Pfreundschuh, Marita Kloess, Rudolf Schmits, +22

Blood